Loading stock data…
MDGL
$513.72-3.67 (-0.71%)
Market ClosedLast close May 1
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Madrigal Pharmaceuticals, Inc. in the Healthcare sector is trading at $513.72. The stock is currently 16% below its 52-week high of $615.00, remaining 9.5% above its 200-day moving average. Technical signals show neutral RSI of 40 and bearish MACD signal, explaining why MDGL maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 40) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$513.72
Potential Upside
5%
Whystock Fair Value$539.41
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Mean target$673.29+31.1%
Range$536.00 – $964.00
Fundamentals
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor bet...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.14B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.01
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-46.77%
Volume
Today's trading volume
186,480
Recent News
Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for
CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Madrigal (MDGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist
These companies boast significant upside potential.
Is Madrigal Pharmaceuticals (MDGL) Still Attractively Priced After Its 20% Monthly Surge?
If you are wondering whether Madrigal Pharmaceuticals' current share price reflects its true worth, you are not alone. This article focuses squarely on what the latest data says about value. The stock closed at US$519.61, with returns of 20.4% over the last 30 days, 63.8% over 1 year and a very large gain over 5 years. This naturally raises questions about how much upside or downside may now be priced in. Recent moves in the share price have played out against a backdrop of ongoing...
Madrigal Pharmaceuticals (MDGL) Surged on Strong Sales of Its Rezdiffra Drug
Janus Henderson Investors, an investment management company, released its “Forty Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. shares increased following positive news about corporate earnings. Economic growth has remained relatively stable despite challenges such as a government shutdown, policy headwinds, and slower-than-expected employment growth. Excitement around artificial […]